Search research articles
Contact Us
Filters
Showing results (161-170 of 277) with videos related to
Page
of 28
Sort By:
Oncotarget
|
May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
Ming-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
Muhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
Oncotarget
|
February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
Ishwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
David S Hong, Patricia LoRusso, Omid Hamid, et al.
JCO Precision Oncology
|
February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced Malignancies
Sigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Oncotarget
|
October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancer
Yudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
NPJ Precision Oncology
|
February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2015
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz, Jayesh Desai, Emily Chan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
Suzanne George, Ping Chi, Michael C Heinrich, et al.
The Oncologist
|
October 6, 2022
Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures
Mohamed A Gouda, Dzifa Y Duose, Morten Lapin, et al.
Page
of 28
Search research articles
Search
Showing results (161-170 of 277) with videos related to
Sort By:
Page
of 28
Oncotarget
|
May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
Ming-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
Muhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
Oncotarget
|
February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
Ishwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
David S Hong, Patricia LoRusso, Omid Hamid, et al.
JCO Precision Oncology
|
February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced Malignancies
Sigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Oncotarget
|
October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancer
Yudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
NPJ Precision Oncology
|
February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2015
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz, Jayesh Desai, Emily Chan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
Suzanne George, Ping Chi, Michael C Heinrich, et al.
The Oncologist
|
October 6, 2022
Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures
Mohamed A Gouda, Dzifa Y Duose, Morten Lapin, et al.
Page
of 28